KR20230162788A - 항-세라마이드 항체를 이용한 상처 치유 증진 - Google Patents

항-세라마이드 항체를 이용한 상처 치유 증진 Download PDF

Info

Publication number
KR20230162788A
KR20230162788A KR1020237035170A KR20237035170A KR20230162788A KR 20230162788 A KR20230162788 A KR 20230162788A KR 1020237035170 A KR1020237035170 A KR 1020237035170A KR 20237035170 A KR20237035170 A KR 20237035170A KR 20230162788 A KR20230162788 A KR 20230162788A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antigen
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035170A
Other languages
English (en)
Korean (ko)
Inventor
리차드 코레스닉
줄리아 버시크
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
보드 오브 트러스티즈 오브 미시건 스테이트 유니버시티
메모리얼 하스피틀 포 캔서 앤드 얼라이드 디지즈스
슬로안-케테링인스티튜트퍼캔서리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터, 보드 오브 트러스티즈 오브 미시건 스테이트 유니버시티, 메모리얼 하스피틀 포 캔서 앤드 얼라이드 디지즈스, 슬로안-케테링인스티튜트퍼캔서리서치 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20230162788A publication Critical patent/KR20230162788A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237035170A 2021-03-16 2022-03-15 항-세라마이드 항체를 이용한 상처 치유 증진 Pending KR20230162788A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161758P 2021-03-16 2021-03-16
US63/161,758 2021-03-16
PCT/US2022/020385 WO2022197703A1 (en) 2021-03-16 2022-03-15 Wound healing enhancement with anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
KR20230162788A true KR20230162788A (ko) 2023-11-28

Family

ID=83321040

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035170A Pending KR20230162788A (ko) 2021-03-16 2022-03-15 항-세라마이드 항체를 이용한 상처 치유 증진

Country Status (10)

Country Link
US (1) US20240158487A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308231A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024511079A (cg-RX-API-DMAC7.html)
KR (1) KR20230162788A (cg-RX-API-DMAC7.html)
CN (1) CN117320750A (cg-RX-API-DMAC7.html)
BR (1) BR112023018758A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212333A1 (cg-RX-API-DMAC7.html)
IL (1) IL305920A (cg-RX-API-DMAC7.html)
MX (1) MX2023010858A (cg-RX-API-DMAC7.html)
WO (1) WO2022197703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12655229B2 (en) 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) * 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
SG11201700787XA (en) * 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
US12655229B2 (en) * 2020-03-18 2026-06-16 Memorial Sloan Kettering Cancer Center Anti-ceramide antibodies

Also Published As

Publication number Publication date
CA3212333A1 (en) 2022-09-22
CN117320750A (zh) 2023-12-29
MX2023010858A (es) 2023-11-23
WO2022197703A1 (en) 2022-09-22
US20240158487A1 (en) 2024-05-16
IL305920A (en) 2023-11-01
EP4308231A4 (en) 2025-01-29
JP2024511079A (ja) 2024-03-12
EP4308231A1 (en) 2024-01-24
BR112023018758A2 (pt) 2023-11-28

Similar Documents

Publication Publication Date Title
EP2152290B1 (en) Methods for administering anti-il-5 antibodies
RU2704999C2 (ru) Способ лечения кожной инфекции путем введения антагониста il-4r
KR102887037B1 (ko) 호중구 질환을 치료하는 방법
MX2011003013A (es) Formulacion liquida estable de anticuerpos.
CN116327921A (zh) 生物医药组合物
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
AU2022309469B2 (en) Il-13 antibodies for the treatment of atopic dermatitis
MX2012012063A (es) Composiciones y metodos para tratar exacerbacion de la enfermedad pulmonar obstructiva cronica (copd).
CN111741768B (zh) 治疗IgE介导的过敏性疾病
US20240158487A1 (en) Wound healing enhancement with anti-ceramide antibodies
IL324054A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
US20230192827A1 (en) Inhibitors and uses thereof
KR20220070244A (ko) 전신성 강피증 치료용 의약 조성물
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法
CA3117142C (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
RU2800765C2 (ru) ЛЕЧЕНИЕ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
RU2772202C2 (ru) Лечение гнойного гидраденита
WO2024184333A1 (en) Il-22r antibody for use in treating atopic dermatitis
HK40048904B (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
HK40048904A (en) Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa
EA049484B1 (ru) Антитела против хемокинов pan-elr+ cxc для лечения гнойного гидраденита

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000